FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.	APPLICATION NO.
CTLIMM.001CP2	09/776,232
APPLICANT: Kündig, et al.	
FILING DATE: February 2, 2001	GROUP: ~~Unknown~~ 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
PK	1	3,604,417	9/14/71	Stolzenberg et al.			
	2	3,732,865	5/15/73	Higuchi, et al.			
	3	3,760,804	9/25/73	Higuchi, et al.			
	4	3,760,805	9/25/73	Higuchi			
	5	3,760,984	9/25/73	Theeuwes			
	6	3,929,132	12/30/75	Higuchi			
	7	3,987,790	10/26/76	Eckenhoff, et al.			
	8	3,995,631	12/7/76	Higuchi, et al.			
	9	3,995,632	12/7/76	Nakano, et al.			
	10	4,034,756	7/12/77	Higuchi, et al.			
	11	4,203,440	5/20/80	Theeuwes			
	12	4,286,067	8/25/81	Theeuwes			
	13	4,300,558	11/12/81	Eckenhoff et al.			
	14	4,304,232	12/8/81	Michaels			
	15	4,340,048	7/20/82	Eckenhoff			
	16	4,340,054	7/20/82	Michaels			
	17	4,350,271	9/21/82	Eckenhoff			
	18	4,367,741	1/11/83	Michaels			
	19	4,435,173	3/6/84	Siposs et al.			
	20	4,439,199	3/27/84	Arnkraut et al.			
	21	4,450,198	5/22/84	Michaels			
	22	4,455,145	6/19/84	Theeuwes			
	23	4,474,575	10/2/84	Eckenhoff, et al.			
	24	4,498,843	2/12/85	Schneider et al.			
	25	4,526,569	7/2/85	Bernardi			
✓	26	4,552,651	11/12/85	Sandbrook, et al.			

EXAMINER	DATE CONSIDERED
	5/18/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/776,232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Kündig, et al.	
	FILING DATE February 2, 2001	GROUP ~~Unknown~~ 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
PJH	27	4,561,856	12/31/85	Cochran			
	28	4,619,652	10/28/86	Eckenhoff, et al.			
	29	4,643,723	2/17/87	Smit			
	30	4,753,651	6/28/88	Eckenhoff			
	31	4,767,628	8/30/88	Hutchinson et al.			
	32	4,838,862	6/13/89	Baker et al.			
	33	4,855,141	8/8/89	Eckenhoff, et al.			
	34	4,865,598	9/12/89	Eckenhoff			
	35	4,865,845	9/12/89	Eckenhoff, et al.			
	36	4,872,873	10/10/89	Zingerman			
	37	4,898,582	2/6/90	Faste			
	38	4,908,433	3/13/90	Mertlesmann et al.			
	39	4,929,233	5/29/90	Roth et al.			
	40	4,963,141	10/16/90	Eckenhoff			
	41	4,976,966	12/11/90	Theeuwes, et al.			
	42	5,017,381	5/21/91	Maruyama, et al.			
	43	5,023,088	6/11/91	Wong et al.			
	44	5,030,216	7/9/91	Theeuwes et al.			
	45	5,034,229	7/23/91	Magruder, et al.			
	46	5,037,420	8/6/91	Magruder, et al.			
	47	5,057,318	10/15/91	Magruder, et al.			
	48	5,059,423	10/22/91	Magruder, et al.			
	49	5,110,596	5/5/92	Magruder, et al.			
	50	5,110,597	5/5/92	Wong, et al.			
	51	5,135,498	8/4/92	Kam, et al.			
V	52	5,135,523	8/4/92	Magruder, et al.			

EXAMINER	DATE CONSIDERED 5/12/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/778,232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Kündig, et al.	
	FILING DATE February 2, 2001	GROUP ~~Unknown~~ 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
PAK	53	5,137,727	8/11/92	Eckenhoff			
	54	5,169,390	12/8/92	Athayde, et al.			
	55	5,174,999	12/29/92	Magruder, et al.			
	56	5,209,746	5/11/93	Balaban, et al.			
	57	5,221,278	6/22/93	Linkwitz, et al.			
	58	5,223,265	6/29/93	Wong			
	59	5,257,987	11/2/93	Athayde et al.			
	60	5,286,254	2/15/94	Shapland et al.			
	61	5,304,165	4/19/94	Haber et al.			
	62	5,368,562	11/29/94	Blomquist et al.			
	63	5,478,556	12/26/95	Elliott et al.			
	64	5,496,360	3/5/96	Hoffmann et al.			
	65	5,580,859	12/03/96	Felgner et al.			
	66	5,589,466	12/31/96	Felgner et al.			
	67	5,679,647	10/21/97	Carson et al.			
	68	5,698,396	12/16/97	Pfreundschuh			
	69	5,733,548	03/31/98	Restifo et al.			
	70	5,744,316	4/28/98	Lethe et al.			
	71	5,747,269	5/5/98	Rammensee et al.			
	72	5,846,540	12/08/98	Restifo et al.			
	73	5,856,187	01/05/99	Restifo et al.			
	74	5,962,428	10/05/99	Carrano et al.			
	75	6,037,135	03/14/00	Kubo et al.			

EXAMINER	DATE CONSIDERED 5/12/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/776,232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Kündig, et al.	
	FILING DATE February 2, 2001	GROUP ~~Unknown~~ 1644

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
PNH	76	2,147,863	05/26/94	Canada				
	77	74899	08/13/97	Ireland				
	78	EP 93/03175	04/06/95	PCT				
	79	WO 92/21033	11/26/92	PCT				
	80	WO 95/17167	06/25/95	PCT				
	81	WO 96/01429	01/18/96	PCT				
	82	WO 96/27008	09/06/96	PCT				
	83	WO 96/40209	12/19/96	PCT				
	84	WO 98/13489	04/02/98	PCT				
	85	WO 98/14464	04/09/98	PCT				
	86	WO 98/27963	07/02/98	PCT				
	87	WO 98/43611	10/08/98	PCT				

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PNH ✓	88	Bachman, M.F., et al. (1994) In vitro vs. in vivo assays for the assessment of T-and B cell function. Curr. Opin. Immunol. 6:320-326.
✓	89	Cleland, J.L., et al. (1994) Formulation and delivery of proteins and peptides. American Chemical Society, Acs Symposium Series No. 567.
✓	90	Courvalin, P. et al. (1995) Life Sci. 318:1207-1212.
✓	91	Dietrich, G. et al. (1998) Biotechnology 16:181-185.
✓	92	Durrant LG (1997) Cancer vaccines. Anti-cancer drugs. 8:727-733.
✓	93	Grohmann, U. et al. (1991) Intrasplenic Immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. Journal of Immunological Methods. 137:9-15.
✓	94	Haynes, B. F. et al. (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:324-327.
✓	95	Inaba, K., et al. (1992) Identification of proliferating dendritic cell precursors in mouse blood. Journal of Experimental Medicine. 175:1157-1167.
✓	96	Jager, E., et al. (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67:54-62.
✓	97	Jager E. et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes. J.Exp.Med. 187:265-270.
✓	98	Kundig, T.M. et al. (1992) Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. 89:7757-7761.
✓	99	Kundig, T.M. et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 268:1343-1347.

EXAMINER	DATE CONSIDERED 5/12/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/776,232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Kündig, et al.	
	FILING DATE February 2, 2001	GROUP ~~Unknown~~ 1644

OIPE SEP 02 2003 PATENT & TRADEMARK OFFICE

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PNK	100	Kundig, T.M. et al. (1996) On the role of antigen in maintaining cytotoxid T cell memory. Proc. Natl. Acad. Sci. 93:9716-9723.
	101	Moskophidis D. et al. (1995) Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. Journal of Virology. 69:4:2187-2193.
	102	Oehen S. et al. (1992) Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J.Exp.Med. 176:1273-1281.
	103	Oldstone, M. et al. (1995) Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. Journal of Virology. 69:12:7423-7429.
	104	Pantaleo G. et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc. Natl. Acad. Sci. 94:9848-9853.
	105	Peters, R.I. et al. (1984) Tryptohan and serotonin metabolism after sustained tryptophan infusion. Neurochem. Int. 6:5:685-691.
	106	~~Pfeiffer, et al. "Insulin Pump Therapy" 3.1 to 3.2.4 pg. 14-33~~
	107	Puccetti P. et al. (1994) Use of skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur. J. Immunol. 24:1446-1452.
	108	Rammensee, H.G. et al. (1995) MHC ligands and peptide motifs: first listing. Immunogenetics.41:178-228.
	109	Rammensee, H.G. et al. (1997) MHC ligands and peptide motifs. Landes Bioscience Austin Texas. Chapter 4:217-369.
	110	Remington (1985) The science and practice of pharmacy, Nineteenth Edition: Chapters 86-88.
	111	Santus G. et al. (1995) Osmotic drug deliver: a review of patent literature. Journal of Controlled Release. 35:1-21.
	112	Simard, John J.L., et al.; 09/560,465; April 28, 2000; EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS.
	113	Simard, John J.L., et al.; 09/561,074; April 28, 2000; METHOD OF EPITOPE DISCOVERY.
	114	Simard, John J.L., et al.; 09/561,571; April 28, 2000; EPITOPE CLUSTERS.
	115	Simard, John J.L., et al.; 09/561,572; April 28, 2000; EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS.
	116	Sizemore, D.R. et al. (1995) Science 270:299-302.
	117	Speiser, D.E. et al. (1997) Self antigens expressed by solid tumors do not efficiently stimulate naïve or activated T cells: implications for immunotheraphy. J. Exp. Med. 186:645-653.
	118	Steinman R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
	119	Wiseman C. et al. (1993) Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon. Annals of the New York Academy of Sciences. 690:388-391.
	120	Wiseman C.L. et al. (1989) Clinical responses with active specific intralymphatic immunothreraphy for cancer – A phase I-II trial. The Western Journal of Medicine. 151:283-288.
	121	Young J. W. et al. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J.Exp.Med. 183:7-11.
	122	Zipkin I. (1998) Cancer vaccines. BioCentury. 6:A1-A6.

EXAMINER	DATE CONSIDERED 5/12/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.